Honest Company Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Honest Company Inc trades at $5.15 (market cap $558.95M), while Regeneron Pharmaceuticals Inc trades at $794.04 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 146.8× Honest Company Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Honest Company Inc pays none. Which is the better fit depends on your goals.
| HNST | REGN | |
|---|---|---|
Market Cap | $558.95M | $82.06B |
Sector | Consumer Staples | Health |
52-Week High | $5.46 | $812.27 |
52-Week Low | $2.10 | $555.51 |
Enterprise Value | $462.56M | $76.77B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.21, down 0.38% on the day, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported mixed Q2 2026 results with an earnings beat but declining revenue, while maintaining negative profitability metrics including a -3.56% net income margin. Recent strategic exits have impacted top-line performance but improved underlying profitability trends.
The stock faces headwinds from inconsistent earnings performance and negative margins, though improved cash flow and strategic repositioning offer potential upside. Analyst sentiment remains cautious with 30% buy ratings, reflecting concerns about sustained profitability amid ongoing business transformation efforts.
Regeneron Pharmaceuticals (REGN) trades at $794.71, down 1.65% on the day, with strong fundamentals including a P/E of 19.72 and net income margin of 27.86%. The stock is in a bullish technical trend, supported by moving averages, though RSI levels indicate overbought conditions. Recent quarterly EPS results have consistently beaten expectations, and the company maintains robust cash flow from operations of $4.98 billion in 2025. However, multiple class action lawsuits related to clinical trial disclosures present a near-term headwind.
The outlook remains positive due to earnings strength and analyst consensus, but legal risks and high valuation multiples warrant caution. Upside is supported by product growth in Eylea HD and Dupixent, while downside risks include litigation outcomes and potential regulatory scrutiny. The stock trades above the consensus price target of $756.93, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →